Nature Cancer

Article	Citations
The impact of the COVID-19 pandemic on cancer care	363
Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis	338
Pan-cancer image-based detection of clinically actionable genetic alterations	336
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab	246
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer	237
Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer	231
Cancer vaccines: the next immunotherapy frontier	222
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma	202
Overcoming therapy resistance in EGFR-mutant lung cancer	197
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression	177
A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors	166
Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities	164
Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4+ and PDPN+ CAFs to clinical outcome	156
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer	150
Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity	147
Cancer-associated fibroblasts in the single-cell era	147
Fatty acid synthesis is required for breast cancer brain metastasis	147
Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity	144
The metabolic landscape of RAS-driven cancers from biology to therapy	137
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells	134
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology	132
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma	131
Artificial intelligence in histopathology: enhancing cancer research and clinical oncology	129
The current paradigm and challenges ahead for the dormancy of disseminated tumor cells	128
Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology	124

Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer	121
EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer	115
Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity	114
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas	113
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy	110
A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy	110
Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial	109
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia	104
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study	102
A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity	102
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia	101
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma	101
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity	99
Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes	95
The immuno-oncological challenge of COVID-19	94
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort	94
Translational advances in pancreatic ductal adenocarcinoma therapy	92
Applications of organoids for cancer biology and precision medicine	90
Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients	90
Three-dimensional imaging mass cytometry for highly multiplexed molecular and cellular mapping of tissues and the tumor microenvironment	89
The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response	89
A systematic CRISPR screen defines mutational mechanisms underpinning signatures caused by replication errors and endogenous DNA damage	88
Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer	87
SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer	84
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer	82
Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism	82
Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in glioblastoma	81
Resistance to natural killer cell immunosurveillance confers a selective advantage to polyclonal metastasis	80
Targeting public neoantigens for cancer immunotherapy	80
The cGAS–STING pathway and cancer	80
Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy	78
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis	76
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity	75
Emerging strategies for treating metastasis	74
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer	74
Super enhancers define regulatory subtypes and cell identity in neuroblastoma	74
CD4+ T cells in cancer	73
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy	73
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade	73
The T cell differentiation landscape is shaped by tumour mutations in lung cancer	72
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia	72
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer	70
Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors	69
Age-associated mitochondrial DNA mutations cause metabolic remodeling that contributes to accelerated intestinal tumorigenesis	68
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer	67
Bone marrow NG2+/Nestin+ mesenchymal stem cells drive DTC dormancy via TGF-β2	67
Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors	64
Targeting PUS7 suppresses tRNA pseudouridylation and glioblastoma tumorigenesis	64
Neutrophil oxidative stress mediates obesity-associated vascular dysfunction and metastatic transmigration	63
Engineering-enhanced CAR T cells for improved cancer therapy	63

c-Rel is a myeloid checkpoint for cancer immunotherapy	63
Dysregulation and therapeutic targeting of RNA splicing in cancer	63
Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response	63
Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients	62
The present and future of PI3K inhibitors for cancer therapy	62
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study	62
Crowdsourcing a crisis response for COVID-19 in oncology	60
GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision	60
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets	59
Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma	58
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer	57
ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1	55
A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets	55
The CIP2A–TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer	54
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment	54
Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression	54
Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer	54
Combined inhibition of Aurora-A and ATR kinases results in regression of MYCN-amplified neuroblastoma	53
Radiation exposure elicits a neutrophil-driven response in healthy lung tissue that enhances metastatic colonization	53
Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain	53
Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment	52
Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer	52
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study	50
EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer	50
The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome	50
Amending microbiota by targeting intestinal inflammation with TNF blockade attenuates development of colorectal cancer	49
The status of tumor mutational burden and immunotherapy	49
Bystander T cells in cancer immunology and therapy	49
A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance	48
TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer	47
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors	46
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity	46
Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1	45
cfDNA methylome profiling for detection and subtyping of small cell lung cancers	45
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology	44
Targeting purine synthesis in ASS1-expressing tumors enhances the response to immune checkpoint inhibitors	43
Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities	43
Accelerating precision medicine in metastatic prostate cancer	43
Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment	43
An artificial intelligence framework integrating longitudinal electronic health records with real-world data enables continuous pan-cancer prognostication	43
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia	41
The deubiquitinase USP25 supports colonic inflammation and bacterial infection and promotes colorectal cancer	41
An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy	40
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes	40
Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance	40
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response	40
Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells	40
A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types	40
Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis	39
APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis	39
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer	39
Moving pan-cancer studies from basic research toward the clinic	39
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma	38
Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms	38
KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming	38
Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response	38
The cancer-testis lncRNA lnc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription	37
Metabolic adaptation of acute lymphoblastic leukemia to the central nervous system microenvironment depends on stearoyl-CoA desaturase	37
Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy	37
An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukemia	37
Illuminating the noncoding genome in cancer	37
Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect	36
Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma	36
Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors	35
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	35
Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia	34
Advancing Cancer Therapy	34
Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression	34
Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs	34
Cancer cell plasticity during tumor progression, metastasis and response to therapy	34
The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing	33
Activation of p38α stress-activated protein kinase drives the formation of the pre-metastatic niche in the lungs	33
Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways	33
Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy	33
Rethinking cancer clinical trials for COVID-19 and beyond	33
Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer	32
Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors	32
Advances in antibody-based therapy in oncology	32
Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress	32
The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets	32

Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia	31
The IRENA lncRNA converts chemotherapy-polarized tumor-suppressing macrophages to tumor-promoting phenotypes in breast cancer	31
Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia	31
The challenges of implementing low-dose computed tomography for lung cancer screening in low- and middle-income countries	31
Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues	31
GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity	30
Zeb2 drives invasive and microbiota-dependent colon carcinoma	30
Deep learning links histology, molecular signatures and prognosis in cancer	30
Cancer-associated fibroblasts employ NUFIP1-dependent autophagy to secrete nucleosides and support pancreatic tumor growth	29
The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations	29
Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting	29
Pharmacological disruption of the MTDH–SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer	29
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance	29
Delineating the evolutionary dynamics of cancer from theory to reality	29
Discovery through clinical sequencing in oncology	29
Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice	28
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders	28
A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling	28
Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade	27
LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer	27
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling	27
SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes	27
Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse	27